The main objective of this study was to assess the interactions that occur between HER-2/EGFR and dual inhibitors (acting on both HER-2 and EGFR) and, consequently, understand their inhibition mechanisms and propose new models of drugs to treat related diseases, such as breast cancer. The gene discussed is ERBB2; the disease is breast cancer.